Home » Stocks » CDAK

Codiak BioSciences, Inc. (CDAK)

Stock Price: $16.66 USD -0.20 (-1.19%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $16.65 -0.01 (-0.06%) May 13, 4:47 PM
Market Cap 372.87M
Revenue (ttm) 15.97M
Net Income (ttm) n/a
Shares Out 20.33M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $16.66
Previous Close $16.86
Change ($) -0.20
Change (%) -1.19%
Day's Open 17.15
Day's Range 16.40 - 17.79
Day's Volume 106,822
52-Week Range 7.90 - 37.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Key clinical data from first in-human studies of engineered exosome therapeutic candidates, exoIL-12™ and exoSTING™, expected this year –

1 week ago - GlobeNewsWire

– engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic areas – – engEx™ Platform and in vitro and in vivo findings support utility across multiple therapeutic ar...

2 weeks ago - GlobeNewsWire

– exoSTING has demonstrated enhanced potency, preferential activation of antigen presenting cells, and systemic anti-tumor immunity in vivo –

3 weeks ago - GlobeNewsWire

– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND submission planned for H2 2021 –

1 month ago - GlobeNewsWire

– First human proof-of-concept data from exoIL-12™ program confirmed desired product profile and enabled dose selection for further evaluation in patients –

1 month ago - GlobeNewsWire

– Healthy volunteer clinical data for exoIL-12 accepted as a late-breaking abstract –

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, DNLI, EVLO, FHTX, KLDO, MCRB, MRNA ...
2 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...

2 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based ...

3 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK) (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a ...

3 months ago - GlobeNewsWire

– Pharmacodynamic results confirm localized exoIL-12 pharmacologic activity

3 months ago - GlobeNewsWire

– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties –

3 months ago - GlobeNewsWire

– exoIL-12 resulted in no local or systemic treatment-related adverse events –

4 months ago - GlobeNewsWire

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class o...

5 months ago - GlobeNewsWire

– Human clinical testing now underway with Codiak's first two candidates, exoIL-12™ and exoSTING™ –

5 months ago - GlobeNewsWire

– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo –

6 months ago - GlobeNewsWire

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, EBC, OPT, PRAX, SPEL, TARS
6 months ago - Seeking Alpha

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Codiak BioSciences, Inc. (“Codiak”), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today an...

6 months ago - Business Wire

About CDAK

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurod... [Read more...]

Industry
Biotechnology
IPO Date
Oct 14, 2020
CEO
Douglas Williams
Employees
105
Stock Exchange
NASDAQ
Ticker Symbol
CDAK
Full Company Profile

Financial Performance

In 2020, CDAK's revenue was $2.92 million, an increase of 651.29% compared to the previous year's $388,000. Losses were -$91.67 million, 17.6% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CDAK stock is "Strong Buy." The 12-month stock price forecast is 36.67, which is an increase of 120.11% from the latest price.

Price Target
$36.67
(120.11% upside)
Analyst Consensus: Strong Buy